Trastuzumab in HER2-negative Early Breast Cancer as Adjuvant Treatment for Circulating Tumor Cells
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Mar 2017
At a glance
- Drugs Trastuzumab (Primary)
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms TREAT CTC
- 07 Jun 2017 Biomarkers information updated
- 25 Oct 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Mar 2017.
- 25 Oct 2016 Status changed from recruiting to active, no longer recruiting.